Fosters Research
No Result
View All Result
No Result
View All Result
Fosters Research
No Result
View All Result
Home Technical Indicators

Why Is The Milestone Pharmaceuticals (MIST) Stock Rocketing In The Pre-Hours Session?

October 17, 2022
in Technical Indicators

Following positive clinical-trial findings, shares of Milestone Pharmaceuticals Inc. (NASD: MIST) were up 33.92% to trade at $11.37 in pre-market at the last check. MIST stock ended Friday’s session down -5.14% with 0.13 million shares changing hands.

What was shared by MIST?

In patients with paroxysmal supraventricular tachycardia, Milestone Pharmaceuticals (MIST) today reported encouraging topline effectiveness and safety data from the Phase 3 RAPID clinical trial of etripamil, the Company’s experimental calcium channel blocker (PSVT).

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

  • 706 individuals were included in the RAPID study, which was multi-center, randomized, double-blind, and placebo-controlled.
  • Without any kind of medical supervision, patients were randomized 1:1 to receive either an etripamil nasal spray or a placebo.
  • Patients who did not experience symptom alleviation after 10 minutes were instructed to self-administer a repeat dosage of the study medicine in order to optimize the potential therapeutic impact of etripamil.
  • Patients using etripamil showed a very statistically significant and clinically significant improvement in time to PSVT conversion compared to placebo, achieving the primary goal of the RAPID study.
  • When etripamil was used instead of a placebo, a statistically substantially higher percentage of patients converted after 30 minutes, according to a Kaplan Meier analysis.
  • PSVT is a sporadic, disruptive burden on patients, and the only available therapies are expensive, uncomfortable acute care settings.
  • The RAPID trial’s results showed that etripamil-treated patients converted to normal sinus rhythm considerably more frequently than placebo-treated patients, without incurring major adverse effects and without the need for medical care.
  • These findings suggest the possibility that etripamil will provide patients with a clinically significant benefit and serve as a crucial and beneficial tool for their doctors.
  • Overall, mild (68%) to moderate (31%%) RTEAEs were noted for the majority of patients.
  • No major adverse events (AEs) connected to etripamil were recorded.
  • More than 1,600 different patients have now received etripamil dosages of less than 70 mg as a consequence of the Company’s entire PSVT clinical study.

What conclusions has MIST drawn from the data?

In the Etripamil clinical trial, Milestone Pharmaceuticals (MIST) observed a statistically significant decrease in the use of extra medical treatments as well as a statistically significant decrease in visits to the emergency room, according to analyses of pooled data from the NODE-301 and RAPID trials. MIST’s complete findings of Phase 3 RAPID clinical trial are anticipated to be presented at a subsequent medical symposium and submitted for publication in a peer-reviewed journal.

Tags: Milestone PharmaceuticalsMilestone Pharmaceuticals IncMilestone Pharmaceuticals Inc StockMilestone Pharmaceuticals StockMIST StockMIST Stock PriceNASD:MISTNASDAQ:MIST

Related Posts

Is This Why The Titan Medical (TMDI) Stock Rose Extended Trading?

January 3, 2023

Why Has The Aziyo (AZYO) Stock Price Gained 12% In Pre-Market Session?

December 9, 2022

On What Basis Did Gamida Cell (GMDA) Stock Drop -21% In Pre-Market Trading On Tuesday?

November 22, 2022

Why Is The electroCore (ECOR) Stock Plummeting The Pre-Market Session?

November 4, 2022

AVCT Stock Dropped 27% In Pre-Market Session: Why?

September 30, 2022

Is This Why The Virios Therapeutics (VIRI) Stock Is Rising Pre-Hours?

September 20, 2022
Next Post

Do futuristic bulls still own Encore Capital Group Inc. [ECPG] stock?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

Can Frontdoor Inc. (FTDR) stock recover despite sales dropping?

2 months ago

NaaS Technology Inc. (NAAS) – it’s time to buy. Check out key Indicators

2 weeks ago

How should investors evaluate Compass Therapeutics Inc. (NASDAQ:CMPX)?

4 days ago

Can ResMed Inc. (RMD) stock recover despite sales dropping?

1 week ago
logo

Welcome to Fosters Research.
We provide quality information for free in a convenient place and format. You do not need to look for us – the news portal “Fosters Research” meets the reader every morning.

Categories

  • Analyst Opinions
  • Featured
  • Finance
  • Market News
  • Technical Indicators
  • Trending Stocks

Company

  • Home
  • About us
  • Contact

Recent Posts

  • Can Titan Pharmaceuticals Inc. (TTNP) stock recover despite sales dropping?
  • There is little time left for S&T Bancorp Inc. (STBA) to reach its 1-year target estimate. How soon will it surpass it?

Copyright © 2022 fostersresearch

No Result
View All Result
  • Home
  • Analyst Opinions
  • Market News
  • Technical Indicators
  • Trending Stocks

Copyright © 2022 fostersresearch